Colony Group’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Colony Group’s Portfolio CNCR Stock Details CNCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$208K	Buy	18,983 +50	+0.3%	+$610	﹤0.01%	722
2023 Q2	$245K	Buy	+18,933	New	+$248K	﹤0.01%	708
2023 Q1	–	Sell	-17,598	Closed	-$242K	–	796
2022 Q4	$242K	Buy	+17,598	New	+$257K	﹤0.01%	753
2022 Q3	–	Sell	-20,892	Closed	-$317K	–	785
2022 Q2	$317K	Buy	20,892 +2,720	+15%	+$41.7K	0.01%	680
2022 Q1	$327K	Buy	+18,172	New	+$345K	﹤0.01%	704

Other funds holding CNCR

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Colony Group's CNCR Position: Q3 2023 in Review

Colony Group increased its ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) stake by 0.26% in Q3 2023, buying an estimated $610 and bringing the position to 18,983 shares worth $208K. The position accounts for ﹤0.01% of the portfolio, ranked #722.

Colony Group first reported a position in CNCR in Q1 2022 and has held it in 5 quarters since. The position peaked at $327K in Q1 2022. 15 funds tracked by Wall St. Rank hold CNCR as of Q3 2023.

Colony Group held 18,983 shares of ETF Series Solutions Trust Range Cancer Therapeutics ETF worth $208K as of Q3 2023.
Colony Group bought 50 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q3 2023, an estimated $610.
ETF Series Solutions Trust Range Cancer Therapeutics ETF made up ﹤0.01% of Colony Group's portfolio in Q3 2023, its #722 holding.
Colony Group first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q1 2022 and has held it in 5 quarters since.
Colony Group's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $327K in Q1 2022.
15 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q3 2023.

Based on Colony Group's 13F filing for Q3 2023, filed 14 Nov 2023.